Profund Advisors LLC Has $1.63 Million Stock Position in IDEAYA Biosciences, Inc. $IDYA

Profund Advisors LLC boosted its holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) by 127.7% in the fourth quarter, HoldingsChannel reports. The firm owned 47,115 shares of the company’s stock after purchasing an additional 26,424 shares during the period. Profund Advisors LLC’s holdings in IDEAYA Biosciences were worth $1,629,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Farther Finance Advisors LLC boosted its holdings in shares of IDEAYA Biosciences by 171.1% during the 4th quarter. Farther Finance Advisors LLC now owns 919 shares of the company’s stock worth $32,000 after buying an additional 580 shares in the last quarter. ANTIPODES PARTNERS Ltd increased its stake in shares of IDEAYA Biosciences by 49.4% in the 4th quarter. ANTIPODES PARTNERS Ltd now owns 1,150 shares of the company’s stock valued at $40,000 after acquiring an additional 380 shares in the last quarter. Aster Capital Management DIFC Ltd bought a new stake in shares of IDEAYA Biosciences in the 3rd quarter valued at $38,000. Abich Financial Wealth Management LLC acquired a new position in shares of IDEAYA Biosciences during the 3rd quarter valued at $58,000. Finally, Comerica Bank boosted its stake in IDEAYA Biosciences by 36.5% during the fourth quarter. Comerica Bank now owns 2,514 shares of the company’s stock worth $87,000 after acquiring an additional 672 shares in the last quarter. 98.29% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of IDEAYA Biosciences in a report on Tuesday, April 21st. Wells Fargo & Company upped their price objective on shares of IDEAYA Biosciences from $44.00 to $48.00 and gave the company an “overweight” rating in a report on Tuesday, April 14th. Cantor Fitzgerald reissued an “overweight” rating on shares of IDEAYA Biosciences in a research report on Wednesday, February 18th. Royal Bank Of Canada raised their target price on IDEAYA Biosciences from $49.00 to $53.00 and gave the company an “outperform” rating in a research note on Tuesday, April 14th. Finally, Wedbush boosted their target price on IDEAYA Biosciences from $52.00 to $58.00 and gave the company an “outperform” rating in a research report on Tuesday, April 14th. Fifteen analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $50.69.

IDEAYA Biosciences Trading Up 4.7%

NASDAQ IDYA opened at $29.65 on Thursday. The company has a market cap of $2.61 billion, a P/E ratio of -18.53 and a beta of -0.04. The company has a fifty day simple moving average of $31.15 and a 200 day simple moving average of $32.83. IDEAYA Biosciences, Inc. has a 12-month low of $18.25 and a 12-month high of $39.28.

IDEAYA Biosciences (NASDAQ:IDYA) last released its quarterly earnings data on Tuesday, May 5th. The company reported ($1.11) earnings per share for the quarter, missing the consensus estimate of ($1.07) by ($0.04). The business had revenue of $6.56 million for the quarter, compared to analysts’ expectations of $5.04 million. During the same quarter last year, the firm posted ($0.82) EPS. The company’s revenue was down 39.4% on a year-over-year basis. Sell-side analysts predict that IDEAYA Biosciences, Inc. will post -4.28 EPS for the current year.

Insider Activity at IDEAYA Biosciences

In other IDEAYA Biosciences news, Director Jeffrey Stein bought 50,000 shares of the stock in a transaction that occurred on Monday, March 2nd. The shares were bought at an average price of $32.96 per share, for a total transaction of $1,648,000.00. Following the acquisition, the director directly owned 54,281 shares of the company’s stock, valued at approximately $1,789,101.76. The trade was a 1,167.95% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 4.70% of the stock is currently owned by insiders.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences is a clinical-stage precision oncology company dedicated to the discovery and development of novel therapies that exploit synthetic lethality in cancer cells. By targeting key DNA damage response pathways, the company aims to selectively kill tumor cells exhibiting specific genetic vulnerabilities while sparing healthy tissue. IDEAYA’s pipeline includes small-molecule inhibitors designed to address underserved tumor types, and its lead programs are advancing through Phase 1 and Phase 2 clinical trials in multiple oncology indications.

Central to IDEAYA’s approach is its Modular Approach to Precision (MAP) platform, which integrates proprietary genomic and functional screening technologies to identify critical cancer-specific dependencies.